Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPGRADE-TNBC: Paclitaxel Polymeric Micelles, Carboplatin, Iparomilimab and Tuvonralimab in TNBC
NCT06910072Phase 3Enrolling by invitation
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 3 trial of tuvonralimab, paclitaxel in triple-negative breast cancer (TNBC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2025; status: enrolling by invitation.
02
Drugs
tuvonralimabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06910072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910072.